Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration M Stone, T Laughren, ML Jones, M Levenson, PC Holland, A Hughes, ... Bmj 339, 2009 | 683 | 2009 |
Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant … MB Stone, ZS Yaseen, BJ Miller, K Richardville, SN Kalaria, I Kirsch Bmj 378, 2022 | 78 | 2022 |
The FDA Warning on Antidepressants and Suicidality — Why the Controversy? M Stone New England Journal of Medicine 371, 1668-71, 2014 | 62 | 2014 |
Medicare Coverage of Routine Screening for Thyroid Disorders MB Stone, RB Wallace The National Academies Press, 2003 | 54* | 2003 |
Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the US Food and Drug Administration’s … SE Andrade, ME Reichman, K Mott, M Pitts, C Kieswetter, M Dinatale, ... Archives of women's mental health 19, 969-977, 2016 | 49 | 2016 |
Clinical review: relationship between antidepressant drugs and suicidality in adults MB Stone, ML Jones Laughren TP. Memorandum: Overview for December 13, 2006 | 49* | 2006 |
Cardiac safety concerns remain for citalopram at dosages above 40 mg/day ST Bird, V Crentsil, R Temple, S Pinheiro, D Demczar, M Stone American Journal of Psychiatry 171 (1), 17-19, 2014 | 19 | 2014 |
Accuracy of ICD-10-CM encounter diagnoses from health records for identifying self-harm events GE Simon, SM Shortreed, JM Boggs, GN Clarke, RC Rossom, ... Journal of the American Medical Informatics Association 29 (12), 2023-2031, 2022 | 17 | 2022 |
Mortality and antipsychotic drug use in dementia-related behavioral disorders. US Department of Health and Human Services M Stone Food and Drug Administration, Center for Drug Evaluation and Research 3, 1-26, 2005 | 16 | 2005 |
Components and trends in treatment effects in randomized placebo-controlled trials in major depressive disorder from 1979-2016 M Stone, S Kalaria, K Richardville, B Miller American Society of Clinical Psychopharmacology, 2018 | 15 | 2018 |
Effect of paroxetine or quetiapine combined with oxycodone vs oxycodone alone on ventilation during hypercapnia: a randomized clinical trial J Florian, R van der Schrier, V Gershuny, MC Davis, C Wang, X Han, ... Jama 328 (14), 1405-1414, 2022 | 14 | 2022 |
Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat L Xu, A Krishna, S Stewart, K Shea, R Racz, JL Weaver, DA Volpe, ... Clinical and Translational Science 14 (6), 2208-2219, 2021 | 13 | 2021 |
Statistical review and evaluation. Antiepileptic drugs and suicidality M Levenson, C George Rochester, E Mentari, A Hughes, J Feeney III, ... Silver Spring (MD): Food and Drug Administration, 2008 | 9 | 2008 |
Conventional vs. atypical antipsychotic medications M Stone, JA Racoosin, T Laughren New England Journal of Medicine 354 (9), 972-974, 2006 | 9* | 2006 |
Committee on Medicare Coverage of Routine Thyroid Screening. Medicare coverage of routine screening for thyroid dysfunction MB Stone, RB Wallace Washington, DC: National Academies Press, 2003 | 6 | 2003 |
Suicidality and aggression during antidepressant treatment: authors misinterpreted earlier paper from the FDA M Stone BMJ 352, 2016 | 5 | 2016 |
Antiepileptic drugs and suicide attempts in patients with bipolar disorder EK Mentari, M Stone, TA Hammad Archives of general psychiatry 67 (9), 972-972, 2010 | 5 | 2010 |
In Search of a Pony: Sources, Methods, Outcomes, and Motivated Reasoning MB Stone Medical Care 56 (5), 375-381, 2018 | 4 | 2018 |
Prevalence and Consequences of Thyroid Dysfunction MB Stone, RB Wallace Medicare Coverage of Routine Screening for Thyroid Dysfunction, 2003 | 4 | 2003 |
Acute hyperkinetic movement disorders as a multifactorial pharmacodynamic drug interaction between methylphenidate and risperidone in children and adolescents M Mohamoud, Q Chen, D Croteau, C Cheng, K Burkhart, DA Volpe, ... Journal of clinical psychopharmacology 42 (3), 238-246, 2022 | 3 | 2022 |